Real-world analysis of renal cell carcinoma with sarcomatoid differentiation treated with first-line immunotherapy combinations: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Noelle Thundathil(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Andrew Weickhardt(Austin Hospital), Marc Machaalani(Dana-Farber Cancer Institute), J L Lee(Asan Medical Center), Cristina Suárez(Vall d'Hebron Hospital Universitari), Ganes Pranavan(Canberra Hospital), Jeffrey Graham(CancerCare Manitoba), Parker Baumgarten(Alberta Cancer Foundation), J. Connor Wells(Occupational Cancer Research Centre), Ignacio Duran(Marqués de Valdecilla University Hospital), Arnoud J. Templeton(University of Basel), Guillermo de Velasco(Hospital Universitario 12 De Octubre), Salina Lalwani(St Bartholomew's Hospital), Haoran Li(University of Utah), Razane El Hajj Chehade(Harvard University), Rana R. McKay(UC San Diego Health System), Martín Zarbá(University of Calgary), Toni K. Choueiri(Dana-Farber Cancer Institute), David Maj(University of Calgary)
Cited by 0
Related Papers
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
|Annals of Oncology|2019|484
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
|Journal of Clinical Oncology|2014|233
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
|Journal for ImmunoTherapy of Cancer|2022|140